Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a Two-Pill combo tame stubborn high cholesterol?

NCT ID NCT06747936

Disease control Sponsor: Addpharma Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 27, 2026 · Last updated Aug 28, 2026 · Updated 1 time

Summary

This phase 3 trial tests whether combining two experimental drugs, AD-2281 and AD-2282, lowers LDL cholesterol more effectively than a single drug in people with primary hypercholesterolemia. Participants take the pills once daily for 8 weeks. Researchers measure the percent change in LDL cholesterol from baseline to week 8. The study compares the combination against an active control and a placebo.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
A combination of two experimental oral drugs, AD-2281 and AD-2282, taken once daily for 8 weeks
What this could lead to
If the combination works, it could offer a new, more effective daily pill option for lowering LDL cholesterol and managing high cholesterol.
What could go wrong
The trial is relatively small and short, and the combination may not prove more effective than existing treatments. Side effects are possible, and long-term benefits are not yet known.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

129 people

The number who actually took part.

Started

Feb 2025

Finished

May 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

19 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Signed informed consent * Patients with Primary Hypercholesterolemia * Other inclusions applied Exclusion Criteria: * Patients with Secondary Hypercholesterolemia * Other exclusions applied

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Primary hypercholesterolemia are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Primary hypercholesterolemia

Contacts and locations

Locations

  • Severance Hospital

    Seoul, Seoul, 03722, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.